Baiyunshan's Subsidiary Secures Macau Registration for Cefalexin Capsules

Stock News

Jul 20

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA: 600332) has announced that its subsidiary branch, Baiyunshan Pharmaceutical General Factory, has received the Certificate of Pharmaceutical Product Registration for Cefalexin Capsules from the Macau Special Administrative Region's Pharmaceutical Administration.

The application for the registration of Cefalexin Capsules 0.125g was submitted by Baiyunshan Pharmaceutical General Factory to the Macau authority on June 1, 2026, and received preliminary acceptance for review on June 22, 2026.

This medication is indicated for treating infections caused by susceptible bacteria, including respiratory tract infections such as acute tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, and pneumonia, as well as urinary tract infections and skin/soft tissue infections.

The product is an oral formulation and is not suitable for the treatment of severe infections.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1114381602"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114381602\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114381602?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114381602","market":"other","top_or_hot":-1,"title":"Baiyunshan's Subsidiary Secures Macau Registration for Cefalexin Capsules","media":"Stock News","content":"<p>Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA: 600332) has announced that its subsidiary branch, Baiyunshan Pharmaceutical General Factory, has received the Certificate of Pharmaceutical Product Registration for Cefalexin Capsules from the Macau Special Administrative Region's Pharmaceutical Administration.<br><br>The application for the registration of Cefalexin Capsules 0.125g was submitted by Baiyunshan Pharmaceutical General Factory to the Macau authority on June 1, 2026, and received preliminary acceptance for review on June 22, 2026.<br><br>This medication is indicated for treating infections caused by susceptible bacteria, including respiratory tract infections such as acute tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, and pneumonia, as well as urinary tract infections and skin/soft tissue infections.<br><br>The product is an oral formulation and is not suitable for the treatment of severe infections.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan's Subsidiary Secures Macau Registration for Cefalexin Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan's Subsidiary Secures Macau Registration for Cefalexin Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-20 16:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA: 600332) has announced that its subsidiary branch, Baiyunshan Pharmaceutical General Factory, has received the Certificate of Pharmaceutical Product Registration for Cefalexin Capsules from the Macau Special Administrative Region's Pharmaceutical Administration.<br><br>The application for the registration of Cefalexin Capsules 0.125g was submitted by Baiyunshan Pharmaceutical General Factory to the Macau authority on June 1, 2026, and received preliminary acceptance for review on June 22, 2026.<br><br>This medication is indicated for treating infections caused by susceptible bacteria, including respiratory tract infections such as acute tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, and pneumonia, as well as urinary tract infections and skin/soft tissue infections.<br><br>The product is an oral formulation and is not suitable for the treatment of severe infections.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"","article_id":"1114381602","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114381602","pubTimestamp":1784535870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA: 600332) has announced that its subsidiary branch, Baiyunshan Pharmaceutical General Factory, has received the Certificate of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0183":"MSCI概念","BK0096":"民营医院","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","BK0188":"融资融券","BK0097":"医药电商","BK0070":"员工持股","BK0012":"证金概念","BK0196":"行业龙头","00874":"白云山","BK0175":"白马股","BK1606":"中医药概念","BK0239":"医药制造","BK0028":"国家队","BK1197":"保健护理产品经销商"},"translate_title":"白云山子公司获得头孢氨苄胶囊澳门注册","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1,"00874":1},"content_text":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA: 600332) has announced that its subsidiary branch, Baiyunshan Pharmaceutical General Factory, has received the Certificate of Pharmaceutical Product Registration for Cefalexin Capsules from the Macau Special Administrative Region's Pharmaceutical Administration.The application for the registration of Cefalexin Capsules 0.125g was submitted by Baiyunshan Pharmaceutical General Factory to the Macau authority on June 1, 2026, and received preliminary acceptance for review on June 22, 2026.This medication is indicated for treating infections caused by susceptible bacteria, including respiratory tract infections such as acute tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, and pneumonia, as well as urinary tract infections and skin/soft tissue infections.The product is an oral formulation and is not suitable for the treatment of severe infections.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}